Herbal Medicine for Vascular Dementia: An Overview of Systematic Reviews

Author(s): Tae-Hun Kim, Jung Won Kang*

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Vascular dementia (VaD), a severe neurologic condition related to aging of the cerebrovascular structure, has been treated with herbal medications and products. In this overview of systematic reviews (SRs) on the effects of herbal medications, we aimed to summarize the current clinical evidence on the benefits of herbal drugs and to propose an evidence map outlining their effects on VaD.

Methods: SRs assessing their effects on cognitive function or performance and the associated safety, published until December 2018, were located from PubMed, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, China National Knowledge Infrastructure, and Oriental Medicine Advanced Searching Integrated System. A Measurement Tool to Assess systematic Reviews 2 was used to assess their overall confidence. A bubble plot was proposed to present the depth and width of the current status of the evidence supporting the use of individual herbal drugs.

Results: Ten SRs (4 on individual herbal medications and 6 on various herbal drugs) were included. The overall evidence on herbal medicines suggests that they are effective in improving cognitive function and performance. Individual herbal medications including FuFangHaiShe, NaoXinTong, YinDanXing- NaoTong, NaoMaiTai, ShenFuTang, and TongXinLuo showed favourable effects when assessed via a minimal mental state examination score but have limited evidence supporting their effectiveness due to the scarcity of randomized controlled trials. Concerning safety, most SRs did not outline the estimated risk ratio of adverse events.

Conclusion: Herbal medications might have benefits for VaD patients but they need to be evaluated further.

Keywords: Herbal medications, cerebrovascular dysfunction, systematic reviews, vascular dementia, aging, cognitive decline.

[1]
Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42(9): 2672-713.
[http://dx.doi.org/10.1161/STR.0b013e3182299496] [PMID: 21778438]
[2]
Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 2013; 381(9882): 2016-23.
[http://dx.doi.org/10.1016/S0140-6736(13)60221-4] [PMID: 23746902]
[3]
Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004; 52(2): 195-204.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52058.x] [PMID: 14728627]
[4]
Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 2012; 47(11): 816-24.
[http://dx.doi.org/10.1016/j.exger.2012.05.023] [PMID: 22705146]
[5]
D’Onofrio G, Sancarlo D, Addante F, et al. Caregiver burden characterization in patients with Alzheimer’s disease or vascular dementia. Int J Geriatr Psychiatry 2015; 30(9): 891-9.
[http://dx.doi.org/10.1002/gps.4232] [PMID: 25475248]
[6]
Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6(9): 782-92.
[http://dx.doi.org/10.1016/S1474-4422(07)70195-3] [PMID: 17689146]
[7]
McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev 2019; 3(3) CD003154
[PMID: 30891742]
[8]
Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4): CD003120
[http://dx.doi.org/10.1002/14651858.CD003120] [PMID: 12519586]
[9]
Hao Z, Liu M, Liu Z, Lv D. Huperzine A for vascular dementia. Cochrane Database Syst Rev 2009; 2 CD007365
[PMID: 19370686]
[10]
Chang D, Liu J, Bilinski K, et al. Herbal medicine for the treatment of vascular dementia: an overview of scientific evidence. Evid Based Complement Alternat Med 2016; 2016 7293626
[http://dx.doi.org/10.1155/2016/7293626]
[11]
Hempel S, Shekelle PG, Taylor SL, et al. Evidence Map of Acupuncture VA Evidence-based Synthesis Program Reports. Washington, DC: Department of Veterans Affairs 2014.
[12]
Anderson S, Allen P, Peckham S, Goodwin N. Asking the right questions: scoping studies in the commissioning of research on the organisation and delivery of health services. Health Res Policy Syst 2008; 6(1): 7.
[http://dx.doi.org/10.1186/1478-4505-6-7] [PMID: 18613961]
[13]
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008.
[PMID: 28935701]
[14]
Yan X. Di Huang, Yin Zi A traditional Chinese herbal formula, for the treatment of vascular dementia: a meta-analysis of 13 randomized controlled trials. Dalian Medical University Press, Dalian 2014.
[15]
Wu TX, Li QP, Yuan ZY. Yizhi capsule for vascular dementia. Cochrane Database Syst Rev 2007; 2 CD005382
[PMID: 17443586]
[16]
Jirong Y, Xiaoyan Y, Taixiang W, Defen S, Birong D. Zhiling decoction for vascular dementia. Cochrane Database Syst Rev 2004; 4 CD004670
[PMID: 15495123]
[17]
Imai H, Takeshima N, Oda H, Chen P, Sawada E, Furukawa TA. Choto-san versus placebo for patients with dementia: systematic review and meta-analysis. Psychogeriatrics 2017; 17(6): 466-78.
[http://dx.doi.org/10.1111/psyg.12275] [PMID: 28589702]
[18]
Zeng L, Zou Y, Kong L, et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? systematic review with meta-analysis of clinical trials. Phytother Res 2015; 29(12): 1843-57.
[http://dx.doi.org/10.1002/ptr.5481] [PMID: 26443194]
[19]
Xu QQ, Shan CS, Wang Y, Shi YH, Zhang QH, Zheng GQ. Chinese herbal medicine for vascular dementia: a systematic review and meta-analysis of high-quality randomized controlled trials. J Alzheimers Dis 2018; 62(1): 429-56.
[http://dx.doi.org/10.3233/JAD-170856] [PMID: 29439346]
[20]
Qin X, Liu Y, Wu Y, et al. A meta-analysis of Chinese herbal medicines for vascular dementia. Neural Regen Res 2013; 8(18): 1685-92.
[PMID: 25206465]
[21]
Gong D, Xu J, Fan Y. Meta-analysis of clinical trials of oral Chinese herbal prescriptions for treatment of vascular dementia based on mini mental state examination scores. Eur J Integr Med 2015; 7(2): 108-17.
[http://dx.doi.org/10.1016/j.eujim.2014.11.002]
[22]
Ghorani-Azam A, Sepahi S, Khodaverdi E, Mohajeri SA. Herbal medicine as a promising therapeutic approach for the management of vascular dementia: A systematic literature review. Phytother Res 2018; 32(9): 1720-8.
[http://dx.doi.org/10.1002/ptr.6120] [PMID: 29786916]
[23]
Chan ESY, Bautista DT, Zhu Y, et al. Traditional Chinese herbal medicine for vascular dementia. Cochrane Database Syst Rev 2018; 12(12) CD010284
[http://dx.doi.org/10.1002/14651858.CD010284.pub2] [PMID: 30520514]
[24]
Shimada Y, Terasawa K, Yamamoto T, et al. A well-controlled study of Choto-san and placebo in the treatment of vascular dementia. J Trad Med 1994; 11: 246-55.
[25]
Suzuki T, Futami S, Igari Y, et al. A Chinese herbal medicine, choto-san, improves cognitive function and activities of daily living of patients with dementia: a double-blind, randomized, placebo-controlled study. J Am Geriatr Soc 2005; 53(12): 2238-40.
[http://dx.doi.org/10.1111/j.1532-5415.2005.00512_7.x] [PMID: 16398922]
[26]
Kim T-H, Kang JW, Lee TH. Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review, evidence mapping, and network meta-analysis. Maturitas 2018; 118: 29-37.
[http://dx.doi.org/10.1016/j.maturitas.2018.09.005] [PMID: 30415752]
[27]
Matsunaga S, Kishi T, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: an updated meta-analysis of randomized controlled trials. J Alzheimer Dis 2016; 54(2): 635-43.
[http://dx.doi.org/10.3233/JAD-160418] [PMID: 27497482]
[28]
Yuan Q, Wang CW, Shi J, Lin ZX. Effects of Ginkgo biloba on dementia: An overview of systematic reviews. J Ethnopharmacol 2017; 195: 1-9.
[http://dx.doi.org/10.1016/j.jep.2016.12.005] [PMID: 27940086]
[29]
Charemboon T, Jaisin K. Ginkgo biloba for prevention of dementia: a systematic review and meta-analysis. J Med Assoc Thai 2015; 98(5): 508-13.
[PMID: 26058281]
[30]
Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database Syst Rev 2010; 12 CD007769
[PMID: 21154383]
[31]
Fønnebø V, Grimsgaard S, Walach H, et al. Researching complementary and alternative treatments--the gatekeepers are not at home. BMC Med Res Methodol 2007; 7(1): 7.
[http://dx.doi.org/10.1186/1471-2288-7-7] [PMID: 17291355]
[32]
Chan P-C, Xia Q, Fu PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007; 25(3): 211-44.
[http://dx.doi.org/10.1080/10590500701569414] [PMID: 17763047]
[33]
Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008; 29(9): 1109-18.
[http://dx.doi.org/10.1111/j.1745-7254.2008.00869.x] [PMID: 18718180]
[34]
Hosseinzadeh H, Ziaei T. Effects of Crocus sativus stigma extract and its constituents, crocin and safranal, on intact memory and scopolamine-induced learning deficits in rats performing the Morris water maze task. J Med Plants 2006; 5(19): 40-50.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 4
Year: 2020
Page: [394 - 409]
Pages: 16
DOI: 10.2174/1570161117666190618164443
Price: $65

Article Metrics

PDF: 19
HTML: 2